• KOL
    • Bipolar Disorder
    • Joseph Biederman
    • JOSEPH Biederman: Influence Statistics

       JOSEPH Biederman

      JOSEPH Biederman

      Show email address

      Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      JOSEPH Biederman:Expert Impact

      Concepts for whichJOSEPH Biedermanhas direct influence:Bipolar disorder,Hyperactivity disorder,Attention deficit,Deficit hyperactivity,Anxiety disorders,Adults adhd,Panic disorder,Major depression.

      JOSEPH Biederman:KOL impact

      Concepts related to the work of other authors for whichfor which JOSEPH Biederman has influence:Hyperactivity disorder,Attention deficit,Children adhd,Mental health,Executive function,Depressive symptoms.

      KOL Resume for JOSEPH Biederman

      Year
      2022

      Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.

      Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

      2021

      Clinical and Research Program in Pediatric Psychopharmacology, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.

      Massachusetts General Hospital, Harvard Medical School, Boston.

      Department of Psychiatry, Harvard Medical School, Boston, MA USA

      2020

      Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, 55 Fruit Street, YAW 6900, 02114, Boston, MA, USA

      Massachusetts General Hospital, Boston, United States; Harvard Medical School, Boston, MA, United States.

      2019

      Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. Electronic address:

      Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

      2018

      Pediatric Psychopharmacology Program, Division of Child Psychiatry, Massachusetts General Hospital, Boston, Massachusetts

      55 Fruit St, Yawkey 6A, Boston, MA.

      2017

      Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts, USA.

      Harvard Medical School, Department of Psychiatry, Boston, MA, United States.

      Massachusetts General Hospital, Boston, Massachusetts.

      2016

      Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA.

      Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

      2015

      Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital, MA 02114, USA

      Harvard Medical School Deparment of Psychiatry Boston Massachusetts

      Sign-in to see all concepts, it's free!
      Sample of concepts for which JOSEPH Biederman is among the top experts in the world.
      Concept World rank
      atomoxetine pharmacokinetics atomoxetine #1
      nonmedicated adults #1
      pdag mdd #1
      hbr treatment #1
      bupropion adult patients #1
      cantab adults #1
      findings cbcl #1
      infancy complications #1
      parental anxiety disorders #1
      dsm iiir adhd #1
      scales cbcl #1
      study nrp104 #1
      clinicaltrails #1
      risperidone study point #1
      youth bipolar depression #1
      subjects tid #1
      treatment oros mph #1
      placebo combined subtypes #1
      age916 #1
      adhd self‐medicate #1
      development drug disorder #1
      adhd youth athletes #1
      placebo patients dmi #1
      sud opioid dependence #1
      mph cognitive level #1
      adults attention #1
      metaanalysis increased prevalence #1
      positive cbcl #1
      mdd addh dst #1
      comorbid psychopathology youths #1
      stimulant treatment atomoxetine #1
      risperidone treatment adhd #1
      patterns comorbidity #1
      parental panic #1
      dsmiv adhd #1
      adhd adults orosmph #1
      efds #1
      flx norflx #1
      comorbid psychopathology bpd #1
      nicotine disorders #1
      mad cranky irritability #1
      psychiatric comorbidity functioning #1
      tolerability lisdexamfetamine dimesylate #1
      teacher reports #1
      human csf cyclic #1
      learning disabilities disorders #1
      modafinil filmcoated tablets #1
      findings behavioral inhibition #1
      girls atomoxetine #1
      adhd schoolage girls #1
      Sign-in to see all concepts, it's free!

      Prominent publications by JOSEPH Biederman

      KOL-Index: 23285

      BACKGROUND: The ability to recognize and diagnose attention-deficit/hyperactivity disorder (ADHD) has increased in recent years. The persistence of ADHD symptoms puts adolescents with ADHD at risk for long-term adverse psychosocial outcomes.

      OBJECTIVE: The primary goal of this study was to assess the efficacy and safety of mixed amphetamine salts extended release (MAS XR) in the management of adolescents with ADHD.

      METHODS: This was a 4-week, randomized, multicenter, double-blind, ...

      Known for Adolescents Adhd | Mixed Amphetamine Salts | Hyperactivity Disorder | Adderall Xr | Extended Release
      KOL-Index: 22676

      OBJECTIVE: The objective of this study was to evaluate differences in the pharmacodynamic (PD) profile of 2 second-generation extended-release (ER) formulations of methylphenidate (MPH): Metadate CD (MCD; methylphenidate HCl, US Pharmacopeia) extended-release capsules, CII, and Concerta (CON; methylphenidate HCl) extended-release tablets, CII. Little empirical information exists to help the clinician compare the PD effects of the available ER formulations on attention and behavior. ...

      Known for Release Methylphenidate | Comacs Study | Hyperactivity Disorder | Effects Mph | Attention Behavior
      KOL-Index: 19685

      BACKGROUND: Lisdexamfetamme dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal of providing an extended duration of effect that is consistent throughout the day, with a reduced potential for abuse, overdose toxicity, and drug tampering. Following ingestion, the pharmacologically active d-amphetamine molecule is gradually released by rate-limited hydrolysis.

      OBJECTIVES: The aims of this study were to assess the efficacy and tolerability of ...

      Known for Phase Iii | Ldx Placebo | Lisdexamfetamine Dimesylate | Efficacy Tolerability | Hyperactivity Disorder
      KOL-Index: 17815

      OBJECTIVE: Modafinil, which is structurally and pharmacologically different from other agents that are used for the treatment of children with attention-deficit/hyperactivity disorder (ADHD), selectively activates the cortex and has low potential for abuse. Initial studies of the use of modafinil to treat ADHD showed significant improvements in the core symptoms of the disorder, namely inattention, hyperactivity, and impulsivity. This study evaluated a new formulation of modafinil ...

      Known for Modafinil Film | Hyperactivity Disorder | Coated Tablets | Treatment Children | Dose Study
      KOL-Index: 16490

      OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.

      METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...

      Known for Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social
      KOL-Index: 15837

      BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...

      Known for Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures
      KOL-Index: 15092

      OBJECTIVE: To examine (1) moderating effects of oppositional defiant disorder (ODD) on attention-deficit/hyperactivity disorder (ADHD) treatment response and (2) responses of ODD symptoms to atomoxetine.

      METHOD: Children and adolescents (ages 8-18) with ADHD were treated for approximately 8 weeks with placebo or atomoxetine (fixed dosing: 0.5, 1.2, or 1.8 mg/kg/day, b.i.d.) under randomized, double-blind conditions. Among patients with lifetime diagnostic information (n = 293), 39% were ...

      Known for Atomoxetine Treatment | Adhd Odd | Hyperactivity Disorder | Children Adolescents | Oppositional Defiant
      KOL-Index: 15011

      BACKGROUND: Oppositional defiant disorder (ODD)is associated with a high degree of impairment in social skills, family interaction, and academic functioning. Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

      OBJECTIVE: The goal of this study was to assess the efficacy and safety of mixed amphetamine salts extended release (MAS XR) for the treatment of ODD in children and adolescents aged 6 to 17 ...

      Known for Oppositional Defiant Disorder | Mixed Amphetamine Salts | Extended Release | Children Adolescents | Efficacy Safety
      KOL-Index: 15010

      With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...

      Known for Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention
      KOL-Index: 14944

      OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.

      METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...

      Known for Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow
      KOL-Index: 14943

      BACKGROUND: Despite the increasing recognition of comorbid attention-deficit/hyperactivity disorder (ADHD) and bipolar disorder (BPD) in adults, there are no prospective trials of pharmacological agents to treat ADHD in these patients. Given the efficacy of bupropion for ADHD in adults, as well as its use in the management of bipolar depression, we studied the tolerability and efficacy of sustained-release (SR) bupropion in adults with ADHD plus BPD.

      METHODS: This was an open, ...

      Known for Bipolar Disorder | Adults Adhd | Treatment Bupropion | Deficit Hyperactivity | Antidepressive Agents
      KOL-Index: 14852

      OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.

      METHOD: Laboratory-based behavioral observations ...

      Known for Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study

      Key People For Bipolar Disorder

      Top KOLs in the world
      #1
      Eduardo Eduard
      bipolar disorder cognitive impairment acute mania
      #2
      Robert M Post
      bipolar disorder affective illness depressed patients
      #3
      Susan L McElroy
      bipolar disorder binge eating bulimia nervosa
      #4
      Paul E Keck
      bipolar disorder acute mania united states
      #5
      Joseph R Calabrese
      bipolar disorder suicidal ideation rapid cycling
      #6
      Gary S Sachs
      bipolar disorder rapid cycling acute mania

      Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. | Pediatric Psychopharmacology, Department of Psychiatry

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.